Search Clinical Trials
Clinical Trial Listings
Volunteer
Learn About Clinical Trials

Breclav, Czech Republic

Search

Location

Distance

< 2 Miles

Filters

Type

Remote

On Site

Actively recruiting

Accepts healthy volunteers

Location

Distance

< 2 Miles

< 5 Miles

< 10 Miles

< 20 Miles

< 30 Miles

< 40 Miles

< 50 Miles

Entire World

Age

0

0

Gender

Male

Female

Trial Phase

Phase 1

Phase 2

Phase 3

Phase 4

Sponsor

Abbvie

Areteia Therapeutics

Astellas Pharma Inc

Astrazeneca

Bayer

Bristol-myers Squibb

Diagram B.v.

Eli Lilly And Company

Genmab

Hoffmann-la Roche

Incyte Corporation

Ipsen

Janssen Research & Development, Llc

Janssen-cilag Ltd.

Joseph Broderick, Md

Medtronic

Merck Sharp & Dohme Llc

National Hospital Organization Nagoya Medical Center

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Monotherapy Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Phase
3
Span
139 weeks
Sponsor
Sanofi
Kagoshima
Recruiting
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
Phase
3
Span
105 weeks
Sponsor
Sanofi
Kagoshima
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Phase
3
Span
203 weeks
Sponsor
Pfizer
Kagoshima
Recruiting
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
Phase
3
Span
111 weeks
Sponsor
Sanofi
Kagoshima
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Phase
3
Span
365 weeks
Sponsor
Merck Sharp & Dohme LLC
Kagoshima
Recruiting
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Phase
3
Span
265 weeks
Sponsor
Eli Lilly and Company
Kagoshima
Recruiting
A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
Phase
3
Span
148 weeks
Sponsor
Eli Lilly and Company
Kagoshima
Recruiting
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
Phase
3
Span
94 weeks
Sponsor
AbbVie
Kagoshima
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase
3
Span
703 weeks
Sponsor
Merck Sharp & Dohme LLC
Kagoshima
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Phase
3
Span
214 weeks
Sponsor
Merck Sharp & Dohme LLC
Kagoshima
Recruiting

1-10 of 57

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 703.538.7600
Toll Free: 888.838.5578

Disclaimer
Privacy Policy
Term of Use
Do Not Sell My Personal Information